



FIG. 1



Difference in Adjusted Mean Change from Baseline versus Placebo (SE)
[90% Confidence Interval]



Baseline is the last non-missing result with a collection date/time less than the date/time of the first dose of study medication. Values shown on the figure represent the difference in adjusted mean change from baseline (SE) between afimotoran vs placebo. Values next to number of patients represent adjusted mean change from baseline (SE) for afimotoran or placebo.

FIG.3




FIG.4

Select the score in each anatomical location that describes the most severely affected cutaneous lupus-associated lesion

activity

damage

E x t e n s i v e	Anatomical Location	Erythema	Scale/Hypertrophy	Dyspigmentation	Scarring/Atrophy/Panniculitis	Anatomical Location
		0-absent 1-pink/urticarythema 2-red 3-dark red/purple/ violaceous crusted/hemorrhagic	0-absent 1-scale 2-verrucous hypertrophy	0-absent 1-dyspigmentation	0-absent 1-scarred 2-severely atrophic/scarring or panniculitis	
	Scalp				See below	Scalp
	Ears					Ears
	Nose (incl. malar area)					Nose (incl. malar area)
	Rest of the face					Rest of the face
	V-area/neck (frontal)					V-area/neck (frontal)
	Post. Neck &/or shoulders					Post. Neck &/or shoulders
	Chest					Chest
	Abdomen					Abdomen
	Back/Buttocks					Back/Buttocks
	Arms					Arms
	Hands					Hands
	Legs					Legs
	Feet					Feet

Mucous membrane

Dyspigmentation

Mucous membrane lesions (examine if patient confirms involvement)

Report duration of dyspigmentation after active lesions have resolved (verbal report by patient - tick appropriate box)

0-absent
no lesion or alteration

☐ Dyspigmentation usually lasts less than 12 months (dyspigmentation score above remains)
☐ Dyspigmentation usually lasts at least 12 months (dyspigmentation score is doubled)

Alopecia

Recent hair loss
(within the last 30 days as reported by patient)

Yes
No

Divide the scalp into four quadrants as shown. The dividing line between right and left is the midline. The dividing line between frontal and occipital is the line connecting the highest points of the ear lobes. A quadrant is considered affected if there is a lesion within the quadrant.

Alopecia (clinically not obviously scarring)

Scarring of the scalp (judged clinically)

0-absent
1-diffuse non-inflamatory
2-focal or patchy in one quadrant
3-focal or patchy in more than one quadrant

0-absent
3-in one quadrant
4-two quadrants
5-three quadrants
6-affects the whole skull

Total Activity Score
(For the activity score please add up the scores of the left side, i.e. for Erythema, Scale/Hypertrophy, Mucous membrane involvement and Alopecia)

Total Damage Score
(For the damage score, please add up the scores of the right side, i.e. for Dyspigmentation, Scarring/Atrophy/Panniculitis and Scarring of the Scalp)